Altshuler Shaham Ltd Makes New $2.08 Million Investment in OPKO Health, Inc. (NASDAQ:OPK)

Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,411,019 shares of the biotechnology company's stock, valued at approximately $2,082,000. Altshuler Shaham Ltd owned about 0.21% of OPKO Health as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of OPKO Health in the fourth quarter valued at $1,657,000. Marshall Wace LLP increased its stake in shares of OPKO Health by 856.5% during the 4th quarter. Marshall Wace LLP now owns 921,487 shares of the biotechnology company's stock valued at $1,355,000 after acquiring an additional 825,143 shares during the last quarter. Barclays PLC lifted its holdings in shares of OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after acquiring an additional 373,032 shares during the period. Essential Planning LLC. acquired a new stake in shares of OPKO Health in the fourth quarter worth approximately $506,000. Finally, ExodusPoint Capital Management LP purchased a new stake in OPKO Health in the fourth quarter valued at approximately $255,000. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Stock Performance

Shares of OPK stock remained flat at $1.42 during trading hours on Friday. The stock had a trading volume of 2,160,919 shares, compared to its average volume of 3,926,301. The stock has a market capitalization of $953.60 million, a P/E ratio of -7.47 and a beta of 1.78. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $2.04. The company's fifty day simple moving average is $1.67 and its two-hundred day simple moving average is $1.57.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock in a transaction on Friday, February 28th. The shares were purchased at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the purchase, the chief executive officer now directly owns 213,301,448 shares of the company's stock, valued at $364,745,476.08. The trade was a 0.03 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought a total of 814,971 shares of company stock valued at $1,308,192 in the last ninety days. Insiders own 49.69% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on OPK shares. Barrington Research reissued an "outperform" rating and set a $2.25 price objective on shares of OPKO Health in a research note on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.